TW201713686A - Methods for preparing modified von Willebrand factor - Google Patents

Methods for preparing modified von Willebrand factor

Info

Publication number
TW201713686A
TW201713686A TW105116002A TW105116002A TW201713686A TW 201713686 A TW201713686 A TW 201713686A TW 105116002 A TW105116002 A TW 105116002A TW 105116002 A TW105116002 A TW 105116002A TW 201713686 A TW201713686 A TW 201713686A
Authority
TW
Taiwan
Prior art keywords
methods
von willebrand
willebrand factor
preparing modified
modified von
Prior art date
Application number
TW105116002A
Other languages
English (en)
Inventor
Stefan Schulte
Hans-Wilhelm Beltz
Sabine Pestel
Thomas Weimer
Matthias Pelzing
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of TW201713686A publication Critical patent/TW201713686A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW105116002A 2015-05-22 2016-05-23 Methods for preparing modified von Willebrand factor TW201713686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15168934 2015-05-22
PCT/EP2016/061440 WO2016188905A1 (en) 2015-05-22 2016-05-20 Methods for preparing modified von willebrand factor

Publications (1)

Publication Number Publication Date
TW201713686A true TW201713686A (en) 2017-04-16

Family

ID=53191564

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105116002A TW201713686A (en) 2015-05-22 2016-05-23 Methods for preparing modified von Willebrand factor

Country Status (17)

Country Link
US (3) US10772936B2 (zh)
EP (2) EP4089109A3 (zh)
JP (1) JP6651548B2 (zh)
KR (1) KR20180012303A (zh)
CN (1) CN107810194B (zh)
AU (1) AU2016267539B2 (zh)
BR (1) BR112017024714A2 (zh)
CA (1) CA2986625A1 (zh)
DK (1) DK3298036T3 (zh)
ES (1) ES2912300T3 (zh)
HK (1) HK1250724A1 (zh)
IL (1) IL255711A (zh)
MX (1) MX2017014872A (zh)
RU (1) RU2017145002A (zh)
SG (2) SG11201708754XA (zh)
TW (1) TW201713686A (zh)
WO (1) WO2016188905A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3538133B1 (en) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
JP2022538357A (ja) * 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
EP4038182A1 (en) * 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
DE69740154D1 (de) 1996-04-24 2011-05-05 Univ Michigan Gegen Inaktivierung resistenter Faktor VIII
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
ES2218806T3 (es) 1997-01-16 2004-11-16 Neose Technologies, Inc. Sialilacion practica in vitro de glicoproteinas recombinantes.
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
CA2450732A1 (en) 2001-06-14 2002-12-27 John H. Griffin Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
JP2005535588A (ja) 2002-04-29 2005-11-24 バクスター・インターナショナル・インコーポレイテッド 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
WO2004058800A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2572732A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
CN1902222A (zh) 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
SI3130601T1 (sl) 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006071801A2 (en) 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
EP1874815A1 (en) 2005-04-14 2008-01-09 CSL Behring GmbH Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0708832A2 (pt) 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea
PL2032607T5 (pl) 2006-06-14 2017-10-31 Csl Behring Gmbh Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
PT2041270E (pt) 2006-07-13 2013-12-27 Wyeth Llc Produção de glicoproteínas
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
CN101910408A (zh) 2007-12-27 2010-12-08 巴克斯特国际公司 细胞培养方法
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
MY201293A (en) 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
SE537059C2 (sv) * 2012-12-21 2014-12-23 Nätstations Alliansen Ab Elcentral
JP2016522219A (ja) * 2013-06-12 2016-07-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物

Also Published As

Publication number Publication date
EP3298036A1 (en) 2018-03-28
KR20180012303A (ko) 2018-02-05
HK1250724A1 (zh) 2019-01-11
EP4089109A2 (en) 2022-11-16
IL255711A (en) 2018-04-30
JP6651548B2 (ja) 2020-02-19
EP3298036B1 (en) 2022-04-06
AU2016267539B2 (en) 2019-12-05
US20180153968A1 (en) 2018-06-07
ES2912300T3 (es) 2022-05-25
SG11201708754XA (en) 2017-12-28
CA2986625A1 (en) 2016-12-01
US20200368327A1 (en) 2020-11-26
DK3298036T3 (da) 2022-06-07
MX2017014872A (es) 2018-07-06
BR112017024714A2 (pt) 2018-09-11
CN107810194A (zh) 2018-03-16
US11564976B2 (en) 2023-01-31
CN107810194B (zh) 2021-10-08
US10905747B2 (en) 2021-02-02
RU2017145002A (ru) 2019-06-24
US10772936B2 (en) 2020-09-15
US20210121535A1 (en) 2021-04-29
SG10201910900WA (en) 2020-01-30
WO2016188905A1 (en) 2016-12-01
EP4089109A3 (en) 2023-03-01
JP2018515125A (ja) 2018-06-14
AU2016267539A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ725568A (en) Modified j-chain
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2016077639A3 (en) Nanovesicular therapies
TW201713686A (en) Methods for preparing modified von Willebrand factor
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2017006692A (es) Trastornos neurodegenerativos.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
BR112017014229A2 (pt) conjugado, composição, e, método para tratamento de um distúrbio.
WO2014165563A3 (en) Uses of cyclic peptides for treating and preventing atherosclerosis